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1
SIGNIFICANCE
This clinical trial evaluated the effect of a probiotic mixture 
as coadjutant treatment together with topical steroids in 90 
patients with plaque psoriasis. The results showed a larger 
reduction in the score of severity indexes in the probiotic 
group compared with the placebo group. Gut microbiota 
analysis demonstrated the efficacy of the probiotic in mo-
dulation of the composition of the microbiota. After the end 
of the probiotic or placebo intake, patients were followed-
up for 6 months. The results showed a lower risk of relapse 
in patients in the probiotic group.
The aim of this 12-week randomized, double-blind, 
placebo-controlled trial was to determine the efficacy 
and safety of a probiotic mixture in the reduction of 
psoriasis severity. Ninety 18–70-year-old adults with 
plaque psoriasis were randomized into probiotic and 
placebo groups. At 12-week follow-up, 66.7% of pa-
tients in the probiotic group and 41.9% in the placebo 
group showed a reduction in Psoriasis Area and Seve-
rity Index of up to 75% (p < 0.05). A clinically relevant 
difference was observed in Physician Global Assess-
ment index: 48.9% in the probiotic group achieved a 
score of 0 or 1, compared with 30.2% in the placebo 
group. The results of follow-up 6 months after the end 
of the study showed a lower risk of relapse after the 
intake of the probiotic mixture. Analysis of gut micro-
biota confirmed the efficacy of the probiotic in modula-
tion of the microbiota composition.
Key words: psoriasis; dermatology; probiotic; microbiome; 
microbiota.
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Psoriasis is traditionally defined as an immune-med-iated, inflammatory dermatological disease charac-
terized by a chronic-relapsing course and associated 
with multifactorial inheritance. Until recently psoriasis 
was considered to be a dermatological disease only, but 
is currently defined as a systemic one because of the 
involvement of multiple organs with important impact 
on social life and relationships (1). Social, psychological 
and economic impacts are comparable to other chronic 
diseases, such as chronic bronchitis, diabetes mellitus 
or depression (2). The disease affects 0.09–11.4% of the 
population worldwide, with variability between different 
countries (2).
The pathogenesis of psoriasis can be explained by 
dysregulation of immunological cell function, as well as 
keratinocyte proliferation/differentiation. Recently, the 
immunological pathomechanism has been substantially 
clarified (3). The elevation of inflammatory markers, such 
as tumour necrosis factor (TNF)-α, interleukin (IL)-12, 
IL-23 and IL-17, is characteristic in peripheral blood of 
patients with psoriasis (4). Treatment has been based for 
years on the use of topical or systemic immunosuppres-
sants, such as systemic corticosteroids, methotrexate or 
cyclosporine, or phototherapy (narrow-band ultraviolet 
B (UVB) phototherapy, broad-band UVB or psoralen-
UVA photochemotherapy) (5). In recent years, there 
has been marked progress in treatment of the disease 
due to development of drugs such as anti-TNF-α, and 
anti-interleukin (IL)-23 and anti-IL-17 monoclonal anti-
bodies (6, 7). These drugs are generally more effective 
than topical or systemic immunosuppressants; however, 
there is a high economic cost and, rarely, they may cause 
severe side-effects, such as emergence of latent infectious 
diseases, such as tuberculosis or hepatitis B, which re-
quired complex treatment (7, 8). In addition, after some 
time, in a few cases antibodies are produced against these 
drugs, decreasing their effectiveness (9).
Recent findings demonstrate the presence of bacterial 
DNA (bactDNA) in peripheral blood samples from pa-
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tients with psoriasis, accompanied by elevation in blood 
values of inflammatory mediators involved in psoriasis 
pathogenesis, such as TNF-α, interferon (IFN)-γ, IL-1β, 
IL-6 and IL-12, with no concurrent infectious process 
(10). This phenomenon is known as bacterial transloca-
tion from the intestinal lumen and is related to the inte-
grity of the intestinal barrier, which has been described 
in other conditions, such as Crohn’s disease and hepatic 
cirrhosis (11, 12).
The microbiota is the set of microbial species present 
in a given habitat. Interaction of gut microbiota with the 
host has great relevance for development of an individual 
throughout their life. There is large variability among the 
gut microbiota in different individuals, as well as in the 
same person throughout their life. Among its functions 
the gut microbiota serves to maintain the integrity of 
the intestinal barrier, the degradation and digestion of 
nutrients, the production of fatty acids and vitamins, the 
reabsorption of bacterial metabolites and the firing of 
the immune system (13–16). The entire intestinal bac-
terial microbiota can reproduce rapidly while adhering 
easily to the intestinal mucosa. In contrast, there is an 
exogenous source of food intake that usually produces 
less reproductive capacity and less facility of adhesion 
to the intestine (16).
In recent years, in-depth studies have confirmed the 
association between the gut microbiota and certain dis-
orders, such as cirrhosis (17), obesity (18), inflammatory 
bowel diseases (19), diabetes mellitus (20) and central 
neural disorders (21, 22). More recently our group has 
found the same association in patients with psoriasis, 
describing the “microbiome core” as a decrease in the 
genus Bacteroides and an increase in Akkermansia spp. 
compared with the healthy group (23). The understanding 
of these regulatory bacteria mechanisms is a challenge for 
medicine and a future source of new treatments aimed at 
treating both digestive and systemic pathologies (24, 25).
Probiotics are microorganisms that provide health 
benefits when consumed in adequate amounts. Mostly, 
they are lactic acid bacteria and bifidobacteria, which 
normally inhabit the intestine and can produce func-
tional compounds. In general, they protect the host 
from infections by immunomodulation, increasing the 
production of immunoglobulins or activating the action 
of mononuclear cells and lymphocytes (26). These bac-
teria can colonize the intestine transiently and survive 
during intestinal transit. In addition, their adhesion to 
the epithelium modifies the local immune response of 
the host (27, 28). Some of them have been tested for 
their positive effects in pathological conditions, such as 
diarrhoea, vaginitis, immunological disorders, lactose 
intolerance, hypercholesterolaemia or food allergy (29, 
30). Among them, several publications have evaluated 
the effect of specific probiotic strains in Crohn’s disease, 
a pathology with higher incidence in psoriatic patients 
than in the general population. Both diseases have in 
common the pathophysiological phenomenon of bacterial 
translocation (10, 31–33).
Based on previous studies, we hypothesized that the 
use of a probiotic may have a beneficial role in the treat-
ment of psoriasis (10, 34–36). To our knowledge, there 
are no previous clinical trials using probiotics in psoria-
sis, hence the results obtained here are the first clinical 
results on the use of these microorganisms in patients 
with psoriasis. The primary goal was to determine the 
percentage of patients with clinical response during the 
study. For this, Psoriasis Area and Severity Index (PASI) 
was evaluated, considering as a positive result a PASI 
reduction of at least 75% of the score obtained at the 
beginning of the study (PASI75).
METHODS
A double-blind, placebo-controlled study with randomization by 
baseline variables (ratio 1:1) was performed from May 2015 to 
October 2016. The study received approval from the Ethics Com-
mittee for Clinical Research of the Hospital General Universitario 
de Alicante, accredited by the Spanish Medicines Agency, and was 
registered in the American Registry of Clinical Trials (Clinical-
Trial.gov identifier: NCT02576197).
Study population
Patients attending the dermatological outpatient clinic were asked 
to participate in the study if they met all of the inclusion criteria: 
age between 18 and 70 years, diagnosis of plaque psoriasis at least 
one year prior to the study, mild or moderate severity (PASI>6) 
and informed consent signed. In women of childbearing age, a 
previous negative pregnancy test was carried out and the use of 
barrier measures was required in their sexual relations during 
study participation. Patients were ineligible if they had had ex-
posure to systemic corticosteroids, methotrexate, cyclosporine, 
or biologic drugs in the previous 3 months, antibiotics in the 
previous 2 weeks, signs of bacterial infection, the diagnosis of 
liver disease with Child-Pugh C index, chronic renal insufficiency 
with creatinine clearance < 50 ml/min or serum creatinine > 1.5 
mg/dl, chronic endocrine, respiratory, neurological or moderate 
to severe cardiovascular disease, as well as concomitant skin 
disease prior to the start of the study. Criteria for withdrawal 
were serious adverse events at the discretion of the investigator, 
violation of the inclusion criteria, treatment deviation understood 
as 3 consecutive days without taking the medication under study 
and requirement of medication for another concomitant pathology 
not allowed in the study.
Participants, recruitment and randomization 
From May 2015 to October 2016, 90 patients were recruited and 
evaluated by 3 dermatologists. Patients were assigned to one of 
the two trial arms (probiotics or control) following a computerized 
randomization list previously prepared by a blinded statistician 
for the treatment administered and for the results during all data 
analysis. Randomization was performed according to the baseline 
variables: sex, age and age of onset of psoriasis. 
Procedure
All patients received treatment during the 12-week study period 
with topical corticosteroid betamethasone in combination with 
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calcipotriol, according to the guidelines for the management of 
psoriasis (37). After being randomized, participants in the probiotic 
group received daily a size 0 hard gelatin capsule containing a 
mixture of 3 probiotic strains in 1:1:1 ratio, freeze-dried powder 
with maltodextrin as a carrier and patients in the placebo group 
received a capsule containing only maltodextrin. The probiotic 
and placebo capsules were matched for size, shape, and volume 
of contents, and were dispensed by the pharmacy department staff. 
The composition of this probiotic mixture was Bifidobacterium 
longum CECT 7347, B. lactis CECT 8145 and Lactobacillus 
rhamnosus CECT 8361 with a total of 1×109 colony-forming units 
(CFU) per capsule, formulated on maltodextrin. 
This mixture of probiotics was selected based on previous 
data: oxidative stress has been associated with psoriasis (38), and 
strain B. lactis CECT 8145 and L. rhamnosus CECT 8361 have 
previously shown antioxidant properties in the Caenorhabditis 
elegans model (39). Strain B. longum CECT 7347 has an anti-in-
flammatory profile (34, 40) and modulates the gut microbiota (34).
The trial protocol established that patients with PASI score 
greater than or equal to 6 would be prescribed betamethasone 
dipropionate 0.25% together with calcipotriol (Daivobet®) once 
a day (in the night before going to sleep), and patients with PASI 
below 6 would be prescribed mometasone furoate 0.1% (Elocom®).
Outcome measurements
Two clinical outcomes were evaluated to determine the percentage 
of patients with clinical response in each treatment group during 
the study. For this, PASI score and PGA index (Physician Global 
Assessment) were evaluated at the time of inclusion, at week 2, 6 
and at the end of the 12-week follow-up period. Topical steroids 
prescription was adjusted according to PASI observed at each visit, 
as explained in the previous section. Other secondary outcomes 
were laboratory values and, for this purpose, peripheral blood 
samples were collected at baseline and after 12 weeks of treatment 
and analysed for inflammatory markers values of TNF-α, IFN-γ, 
IL-1β, IL-6, IL-12 and IL-23. Finally, a stool sample was obtained 
from all patients at baseline and at the end of the study. The sample 
was immediately frozen and stored at –80°C until processing for 
massive genome sequencing according to our previous published 
strategy (23). Microbiome profiles were classified in order to 
better analyse the microbiome into groups based on Arumugam 
et al. (41), that each of the groups is named as enterotypes 1, 2 
or 3 depending on higher the presence of bacteria belonging to 
Bacteroides, Prevotella and Ruminococcus genera, respectively. 
Finally the alpha diversity Shannon index, a measure of diversity 
that combines species richness (the number of species) and their 
relative abundances were calculated.
As a measure to establish the safety of the study probiotic mix-
ture, all side-effects that appeared during the study were recorded 
and the results were compared between the 2 study groups.
Post clinical trial follow-up
This information was collected out of protocol study, when inter-
vention with the probiotic or placebo had finished. Patients were 
followed-up during the 6 months of the post-intervention outcome 
period. Every month during this period, a telephone follow-up 
monthly visit was scheduled, and patients were asked about the 
clinical situation. When a patient described a relapse during this 
follow-up period of 6 months, he or she was requested to attend the 
clinic for a face to face visit, no later than 3 days after the relapse 
began. In the outpatient medical centre, a dermatologist evaluated 
the patient and documented their PASI score to assess the relapse, 
defined in the clinical trial as an increase in PASI score compared 
with the PASI result at the end of the 12-week treatment period.
Sample size and statistics
According to the trial protocol, 45 patients per group would be 
needed to detect a difference in clinical improvement as evaluated 
by the PASI score, assuming 10% lost to follow-up, 0.05 type-I 
error and 80% power to detect a difference of 30% of response 
between groups in a 2-sided t-test.
Data were analysed as intention-to-treat and the last available 
value was not carried forward for missing observations. Quantita-
tive variables were summarized as means and standard deviations 
(SD) or median and interquartile range (IQR) and categorical 
variables are summarized with proportions.
The main efficacy variable was defined as binary: “a proportional 
reduction in PASI of 75% or more of baseline PASI” (PASI75). 
Following the trial protocol, once a patient reached success in a 
visit their outcome of success was retained for the posterior visits. 
At each visit we reported the probability of success in each arm 
with the corresponding exact 95% confidence interval (95% CI) 
and we compared these probabilities between the two arms using 
Fisher’s exact test for comparison of 2 proportions. 
Regarding the analysis of PGA, we dichotomized the PGA scale 
into 2 categories: clear (original PGA levels “clear” or “almost 
clear”) vs. non-clear (rest of original PGA levels). In each visit we 
estimated the proportion of clear PGA in each group with exact 
95% confidence intervals (95% CI) and compared these probabi-
lities between groups using the Fisher’s exact test.
The number of days of topical steroid usage was not recorded 
during the trial. However, the trial protocol established that pa-
tients with PASI<6 would only be prescribed mometasone 0.1% 
instead of betamethasone 0.25% and calcipotriol for patients with 
PASI≥6. To analyse the difference in topical steroids between 
groups we compared the proportion of patients with PASI<6 
between the two trial arms at each visit using a Fisher’s exact test. 
Biochemical laboratory variables and inflammatory biomarkers 
were analysed as continuous variables. We used linear regression 
models of the difference between baseline and the 12-week value, 
regressed on the treatment group and adjusted by the baseline 
value (centred on the mean of the control group) to account for 
regression to the mean effect. In the case of microbiome analysis, 
alpha diversity was conducted using the specaccum program in 
the vegan package as implemented for R and data was compared 
among each treatment groups and with those in healthy population 
(based on the data from the Human Microbiome Project (HMP 
(http://hmpdacc.org/)) following the same strategy as previously 
published (23). All statistical analyses were performed using 
statistics R version 3.2.3.
RESULTS
A total of 90 patients diagnosed with psoriasis were 
enrolled in the study and assigned to one of the two 
treat ment arms. Baseline characteristics of these patients 
are described in Table I. CONSORT recommendations 
for reporting of randomized clinical trials were followed 
(Fig. 1). Two of 90 (2.2%) patients did not complete the 
study. Overall reasons for missing data were unrelated 
either to the treatment or to the outcome; therefore effect 
bias is not expected. 
Comparison of PASI and PGA between treatment groups
At baseline there were no noticeable differences between 
arms, but in the evaluation at week 12 (end of follow-
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Table I. Baseline characteristics of study participants in both 
intervention groups
Probiotic
(n = 46)
Placebo
(n = 44)
Demographics
Age at inclusion, years, mean (SD) 41.57 (13.23) 43.09 (10.32)
Years of evolution, mean (SD) 19.22 (13.73) 20.98 (13.69)
Female sex, n (%) 27 (58.70) 27 (61.36)
Weight, kg, mean (SD) 76.29 (18.69) 79.22 (13.47)
Height, cm, mean (SD) 169.96 (9.91) 170.63 (9.27)
Non-smoker, n (%) 33 (71.74) 30 (68.18)
Current smoker (>10 cigarettes/day), n (%) 9 (19.57) 9 (20.45)
Smoker (1–9 cigarettes/day), n (%) 4 (8.70) 5 (11.36)
Familiar psoriasis, n (%) 12 (26.09) 19 (43.18)
Haematological test, mean (SD)
Haemoglobin, g/dl 14.63 (1.53) 14.54 (1.30)
Leucocytes count, /µl 8.06 (2.38) 7.63 (1.98)
Eosinophils count, /µl 2.93 (2.08) 2.50 (1.53)
AST, UI/ml 23.04 (7.39) 25.25 (12.81)
ALT, UI/ml 22.48 (11.21) 27.39 (18.71)
Creatinine, mg/dl 0.79 (0.18) 0.80 (0.15)
Glucose, mg/dl 90.96 (11.84) 93.55 (15.39)
Cholesterol, g/dl 194.39 (42.38) 200.16 (30.75)
Triglycerides, g/dl 151.45 (99.51) 159.14 (94.98)
C-reactive protein, mg/l 0.32 (0.58) 0.48 (0.48)
Tumour necrosis factor-α, pg/ml 14.98 (1.61) 15.18 (1.80)
Interleukin 23, pg/ml 29.59 (2.83) 29.52 (2.68)
Interleukin 12, pg/ml 88.68 (27.42) 92.66 (45.99)
Interferon-γ, pg/ml 19.06 (1.16) 16.56 (1.78)
Interleukin 1β, pg/ml 9.28 (2.43) 10.89 (3.16)
Interleukin 6, pg/ml 10.13 (2.54) 11.02 (2.83)
Severity of psoriasis
PASI score, mean (SD) 11.68 (5.11) 11.45 (4.24)
PASI ≥ 10, n (%) 23 (50) 20 (45.5)
PGA moderate or worsen, n (%) 36 (78.26) 36 (81.81)
SI conversion factors: To convert haemoglobin to g/l, multiply by 10; to convert AST 
and ALT to µkat/l, multiply by 16.67; to convert creatinine to mmol/l, multiply by 
0.0884; to convert glucose to mmol/l, multiply by 0.0555; to convert cholesterol to 
µmol/l, multiply by 0.0259; to convert triglycerides to µmol/l, multiply by 0.0113; 
to convert c-reactive protein to nmol/l, multiply by 9.524.
SD: standard deviation; AST: aspartate transaminase; ALT: alanine transaminase; 
PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment.
Fig. 1. Consolidated Standards of Reporting Trials (CONSORT) 
diagram.
Fig. 3. Psoriasis Area and Severity Index (PASI) <6 evolution. 
Point estimates with 95% exact confidence intervals of the proportion of 
patients with PASI <6 (interrupt prescription of betamethasone) at each 
visit. p-values are obtained from Fisher’s exact tests comparing the 2 
proportions at each time-point.
Fig. 2. Psoriasis Area and Severity Index (PASI)75 evolution. 
Point estimates with 95% exact confidence intervals of the proportion of 
patients with a reduction of PASI of up to 75% from baseline (PASI75) at 
each visit. p-values are obtained from Fisher’s exact tests comparing the 
2 proportions at each time-point.
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up), differences arose in 30 of 45 (66.7%) patients in 
the probiotic group and 18 of 43 (41.9%) in the placebo 
group, showing a reduction in PASI up to 75% (p-value 
for the difference of proportions was 0.0317). Proportions 
and 95% CI for different weeks are shown in Fig. 2. 
Three of 43 (7.0%) patients in the placebo group had 
a severe relapse and required treatment with anti-TNF 
biologic drugs. The proportion of patients with PASI<6 
(and therefore with no prescription of betamethasone) 
was greater in the intervention group than in the control 
group in all the follow-up visits, reaching (91%) in the 
probiotic group and (77%) in the control group in the 
last visit. However, in none of the visits the test for dif-
ferences between the groups produced p-values < 0.05 
(Fig. 3). PGA distributions at different visits in both 
groups are shown in Fig. S11. There were differences in 
the proportion of patients with a “clear PGA” between the 
two groups at week 12 visit: 22 patients (48.9%) in the 
probiotic group and 13 patients (30.2%) in the placebo 
group but the p-value for the difference of proportions 
was as large as 0.0853 (Fig. 4). 
Blood marker levels and microbiota composition
Baseline levels of inflammatory markers in both groups 
of treatment are described in Table I. No difference was 
observed comparing both groups of patients at the end 
of the intervention.
Based on the microbiome composition, the enterotype 
distribution of the patients at baseline was 49 (56.3%) 
enterotype 1, 7 (8.1%) enterotype 2, and 31 (35.6%) 
enterotype 3. There was no difference between the 2 
analysed groups at the beginning of the study. Compa-
ring the percentage of patients that did not change the 
enterotype at the end of the study in the probiotic and 
placebo groups, no statistically significant differences 
were found in any of the enterotypes (enterotype 1: 
56.7% vs. 46.2%; enterotype 2: 0% vs. 42.3% and 
enterotype 3: 84.6% vs. 53.3%). Interestingly, there is 
a total disappearance of the genera Micromonospora 
and Rhodococcus and an increase in Collinsella and 
Lactobacillus in the probiotic group, comparing initial 
and final time-points (Fig. S21). In the case of placebo no 
trend was detected. Also, bacterial diversity was detected 
at the final time-point closer to the healthy population, 
although without significant statistical differences in 
both treatment groups (Fig. S31).
Post clinical trial follow-up
During the post study follow-up there were 9 relapses out 
of 45 patients (20%) included in the probiotic group, and 
18 relapses of 43 patients assigned to the placebo group 
(41.9%) The p-value for the log-rank test was 0.027 (Fig. 
5). Detailed information is shown in Table SI1.
Adverse events
The number of side-effects due to interventional medica-
tion was low and, in all cases, patients continued in the 
study until the end of the 12-week follow-up interven-
tion. No relevant unintended effects were associated with 
either the probiotic or the placebo intake. Furthermore, no 
severe side-effects were observed in either study group 
during the intervention and no patient was withdrawn 
due to side-effects of the treatment.
DISCUSSION
During recent years, several authors have reported the 
relationship between gut microbiome and psoriasis. To 
our knowledge, the clinical trial reported here explores 
for the first time the role of a mixture of probiotics admi-
nistered to patients with psoriasis, both in the evolution 1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3305
Fig. 4. Physician Global Assessment (PGA) evolution. Point estimates 
with 95% exact confidence intervals of the proportion of patients who 
reached a “clear” PGA index (as defined in the methods) at each visit. 
p-values are obtained from Fisher’s exact tests comparing the 2 proportions 
at each time-point.
Fig. 5. Post clinical trial follow-up. Proportion of patients without a new 
relapse in the 6-month follow-up period in probiotic and placebo groups.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
V. Navarro-López et al.6
www.medicaljournals.se/acta
of the activity of psoriasis and in the composition of the 
patients’ gut microbiota. Several variables, such as the 
use of antibiotics, immunomodulatory drugs and other 
concomitant allergenic diseases were controlled.
The results of this study show a beneficial effect of this 
probiotic blend, in reducing the severity of psoriasis when 
administered as coadjutant therapy together with topical 
corticosteroid. The mean variable PASI75 shows a higher 
response rate in patients in the probiotic group than in 
those in the placebo group (66.7% vs. 45.2%) at the end 
of the 12-week follow-up. Compared with the placebo 
group at the 12-week follow-up visit, the probiotic group 
also showed a higher proportion of patients classified as 
clear or almost clear in the PGA index and a lower need 
for prescription of betamethasone steroids (although the 
statistical tests did not reach 5% level of significance for 
either of these outcomes).
Concerning gut microbiota and its changes during 
the interventional period of the study, a disappearance 
of the problematic Micromonospora and Rhodococcus 
and an increase in the positive genera Collinsella and 
Lactobacillus were detected in the group receiving 
probiotics. Particularly noticeable are the elimination of 
Rhodococcus, a bacteria related to septicaemia and bio-
film production (42), and the increase in Collinsella and 
Lactobacillus, genera associated with better gut health 
(43). An abundance of Th17 cells is notorious in skin and 
intestine. These cells are related to the pathogenesis of 
chronic inflammatory skin diseases, including psoriasis 
(44, 45). Intestinal microbiome contributes to balance 
Th17 cells and their counterpart regulatory T cells (46). 
Changes in the microbiota described in this clinical trial 
in the probiotic group could thus explain, at least in part, 
the positive effect of the probiotic mixture on the evolu-
tion of psoriasis.
A follow-up of patients for 6 months after the end of 
the intervention shows that patients previously treated 
with the probiotic mixture have a lower risk of relapse 
than those who previously received placebo. This better 
evolution, together with changes observed in the gut 
microbiota in patients previously receiving the probio-
tic blend, suggest a preventive role of probiotics (more 
time free of relapse), and not only a therapeutic benefit 
of coadjutant treatment.
No relevant unintended effects and no severe side-
effects were observed in either group during the inter-
vention, demonstrating the safety status of the probiotic 
mixture used in this study.
In conclusion, the results of this study indicate a pos-
sible positive effect of the probiotic mixture in reducing 
the severity of psoriasis when administered to patients 
with psoriasis together with the topical corticosteroid 
betamethasone and calcipotriol, according to the guide-
lines for the management of psoriasis. 
Study limitations
This is the first clinical trial to assess the effectiveness 
of probiotics on the clinical evolution and microbiota 
composition of patients with psoriasis; no previous in-
formation is available for this probiotic or other probiotic 
strains. The fact that the study was performed in patients 
over 17 years of age, all from a single clinical centre, is 
another limitation. Finally, further limitations were the 
use of a single dose of the probiotic, the single period of 
treatment with short follow-up of 12 weeks, and the fact 
that the dose of topical corticosteroid was not recorded. 
More studies that include patients from a different 
areas, especially those consuming different diets are ne-
cessary to further assess these results. Also, new clinical 
trials should consider the inclusion of patients younger 
than 18 years, the use of different doses of probiotics, 
different durations of probiotic administration and dif-
ferent strains, for comparison with the current results.
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Supplementary material to article by V. Navarro-López et al. ”Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in 
Patients with Psoriasis: a Randomized Controlled Clinical Trial”
Fig. S1. Physician Global Assessment (PGA) categories. Proportion of patients in 
each PGA category in the 12-week follow-up period in probiotic and placebo groups.
Fig. S2. Changes in gut microbiota. Levels of the genera Colinsella, Lactobacillus, 
Micromonospora and Rhodococcus in probiotic group at baseline (T1) and after the 12-
week follow-up period (T2).
Fig. S3. Microbiome variability based on Shannon diversity index. Boxplot of 
the Shannon diversity index at baseline (T1) and the 12-week follow-up period (T2) of 
probiotic (Pr) and placebo (Pl) group of the study and the healthy population based on 
the Human Microbiome Project (HMP (http://hmpdacc.org/).
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Supplementary material to article by V. Navarro-López et al. ”Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in 
Patients with Psoriasis: a Randomized Controlled Clinical Trial”
Table SI. Post clinical trial follow-up. Number of patients free of 
relapses and time when relapse occurred.
Time of follow-up 
(months)
Patients free of relapse, 
n (proportion) SE 95% CI
Treatment group: probiotic (n = 45)
1 44 (0.978) 0.0220 0.936–1.000
2 43 (0.956) 0.0307 0.897–1.000
3 39 (0.867) 0.0507 0.773–0.972
4 38 (0.844) 0.0540 0.745–0.957
5 38 (0.844) 0.0540 0.745–0.957
6 36 (0.800) 0.0596 0.691–0.926
Treatment group: placebo (n = 43)
1 39 (0.907) 0.0443 0.824–0.998
2 37 (0.860) 0.0528 0.763–0.971
3 34 (0.791) 0.0620 0.678–0.922
4 28 (0.651) 0.0727 0.523–0.810
5 27 (0.628) 0.0737 0.499–0.790
6 25 (0.581) 0.0752 0.451–0.749
SE: standard error; CI: confidence interval.
